Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein-Reference-Cited by-同舟云学术

Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein

Published:2018-10-31 Issue:7 Volume:40 Page:980-988
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Meng Jian,Liu Xiao-yun,Ma Sheng,Zhang Hua,Yu Song-da,Zhang Yi-fan,Chen Mei-xia,Zhu Xiao-yu,Liu Yi,Yi Ling,Ding Xiao-liang,Chen Xiao-yan,Miao Li-yan,Zhong Da-fang

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.nature.com/articles/s41401-018-0176-6.pdf

Reference24 articles.

1. Li X, Yang CY, Wan H, Zhang G, Feng J, Zhang L, et al. Discovery and development of pyrotinib: a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017;110:51–61.

2. Ma F, Li Q, Chen SS, Zhu WJ, Fan Y, Wang JY, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2017;35:3105–12.

3. Zhu YT, Li L, Zhang G, Wan H, Yang CY, Diao XX, et al. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B. 2016;1033–1034:117–27.

4. Johnson DS, Weerapana E, Cravatt BF. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med Chem. 2010;2:949–64.

5. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov. 2011;10:307–17.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted multimodal synergistic therapy of drug-resistant HER2-positive breast cancer by pyrotinib-ICG self-assembled nanoparticles;American Journal of Cancer Research;2024

2. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now;Breast Cancer Research;2023-10-03

3. Biotransformation research advances – 2022 year in review;Drug Metabolism Reviews;2023-10-02

4. Study of the mass balance, biotransformation and safety of [14C]SHR8554, a novel μ-opioid receptor injection, in healthy Chinese subjects;Frontiers in Pharmacology;2023-09-14

5. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials;Signal Transduction and Targeted Therapy;2023-09-06